Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

Inclusion Criteria: * Must understand and voluntarily sign an informed consent form. * Must be male or female and age 18-55 years at time of consent. * Must be able to adhere to the study visit schedule and other protocol requirements * Have chronic plaque psoriasis for more than 6 months with a PASI score of 12 or greater at Baseline. * Females of childbearing potential (FCBP)‡ must have a negative urine pregnancy test at screening (Visit 1). * Negative PPD at Screening or 3 months earlier. * Have not used any biologic treatment for psoriasis in the past 12 months. Exclusion Criteria: * Inability to provide voluntary consent * Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study * Pregnant, trying to become pregnant or breastfeeding * Prior diagnosis of coronary artery disease (CAD) or heart disease. * Systemic fungal infection * History of past or active mycobacterial infection with any species (including Mycobacterium tuberculosis). Latent Mycobacterium tuberculosis infection as indicated by a positive (more than 15mm induration)Purified Protein Derivative \[PPD\] skin test. Subjects with a positive PPD skin test and documented completion of treatment for latent TB are eligible. Subjects with a positive PPD skin test and not treated or no documentation of completion of treatment are ineligible. * History of recurrent bacterial infection (at least 3 major infections resulting in hospitalization and/or requiring intravenous antibiotic treatment within the past 2 years) * Clinically significant abnormality on the chest x-ray (CXR) at screening. Chest x-rays performed within 3 months prior to start of study drug are acceptable. * Use of any investigational medication within 4 weeks prior to start of study drug or 5 pharmacokinetic/pharmacodynamic half-lives (whichever is longer) * History of Human Immunodeficiency Virus (HIV) infection or Hepatitis C * Positive Hepatitis B Surface antigen at screening * Malignancy or history of malignancy (except for treated \[ie, cured\] basal-cell skin carcinomas \> 3 years prior to screening) * History of any demyelinating disorder such as multiple sclerosis.